GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China SXT Pharmaceuticals Inc (STU:2RY0) » Definitions » EPS (Diluted)

China SXT Pharmaceuticals (STU:2RY0) EPS (Diluted) : €-15.39 (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is China SXT Pharmaceuticals EPS (Diluted)?

China SXT Pharmaceuticals's Earnings per Share (Diluted) for the six months ended in Mar. 2024 was €2.74. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €-15.39.

China SXT Pharmaceuticals's EPS (Basic) for the six months ended in Mar. 2024 was €2.74. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was €-15.39.

China SXT Pharmaceuticals's EPS without NRI for the six months ended in Mar. 2024 was €2.74. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was €-15.39.

During the past 3 years, the average EPS without NRIGrowth Rate was 66.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 8 years, China SXT Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 66.60% per year. The lowest was 61.20% per year. And the median was 63.90% per year.


China SXT Pharmaceuticals EPS (Diluted) Historical Data

The historical data trend for China SXT Pharmaceuticals's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China SXT Pharmaceuticals EPS (Diluted) Chart

China SXT Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EPS (Diluted)
Get a 7-Day Free Trial -753.01 -80.20 -125.23 -20.76 -3.29

China SXT Pharmaceuticals Semi-Annual Data
Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -34.95 -14.76 -9.07 -18.12 2.74

Competitive Comparison of China SXT Pharmaceuticals's EPS (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, China SXT Pharmaceuticals's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China SXT Pharmaceuticals's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China SXT Pharmaceuticals's PE Ratio distribution charts can be found below:

* The bar in red indicates where China SXT Pharmaceuticals's PE Ratio falls into.



China SXT Pharmaceuticals EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

China SXT Pharmaceuticals's Diluted EPS for the fiscal year that ended in Mar. 2024 is calculated as

Diluted EPS (A: Mar. 2024 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-2.851-0)/0.867
=-3.29

China SXT Pharmaceuticals's Diluted EPS for the quarter that ended in Mar. 2024 is calculated as

Diluted EPS (Q: Mar. 2024 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(6.07-0)/1.233
=4.92

EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-15.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


China SXT Pharmaceuticals  (STU:2RY0) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


China SXT Pharmaceuticals EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of China SXT Pharmaceuticals's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


China SXT Pharmaceuticals Business Description

Traded in Other Exchanges
Address
No. 178 Taidong Road North, Jiangsu, Taizhou, CHN, 225300
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.

China SXT Pharmaceuticals Headlines

No Headlines